Muayad F Almahariq1, Thomas J Quinn1, Pravin Kesarwani1, Shiva Kant1, C Ryan Miller2, Prakash Chinnaiyan3,4. 1. Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, U.S.A. 2. Division of Neuropathology, Department of Pathology, O'Neal Comprehensive Cancer Center, Comprehensive Neuroscience Center, University of Alabama School of Medicine, Birmingham, AL, U.S.A. 3. Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, U.S.A.; prakash.chinnaiyan@beaumont.edu. 4. Oakland University William Beaumont School of Medicine, Rochester, MI, U.S.A.
Abstract
AIM: To use inhibition of colony-stimulating factor-1 receptor (CSF-1R) to target tumor-associated macrophages (TAMs) and improve the efficacy of radiotherapy in glioblastoma (GBM). MATERIALS AND METHODS: The CSF-1R inhibitor BLZ-945 was used to examine the impact of CSF-1R inhibition on M2 polarization in vitro. Using an orthotopic, immunocompetent GBM model, mice were treated with vehicle, RT, BLZ-945, or RT plus BLZ-945. RESULTS: BLZ-945 reduced M2 polarization in vitro. BLZ-945 alone did not improve median overall survival (mOS=29 days) compared to control mice (mOS=27 days). RT improved survival (mOS=45 days; p=0.02), while RT plus BLZ-945 led to the longest survival (mOS=not reached; p=0.005). Resected tumors had a relatively large population of M2 TAMs in GBM at baseline, which was increased in response to RT. BLZ-945 reduced RT-induced M2 infiltration. CONCLUSION: Inhibition of CSF-1R improved response to RT in the treatment of GBM and may represent a promising strategy to improve RT-induced antitumor immune responses. Copyright
AIM: To use inhibition of colony-stimulating factor-1 receptor (CSF-1R) to target tumor-associated macrophages (TAMs) and improve the efficacy of radiotherapy in glioblastoma (GBM). MATERIALS AND METHODS: The CSF-1R inhibitor BLZ-945 was used to examine the impact of CSF-1R inhibition on M2 polarization in vitro. Using an orthotopic, immunocompetent GBM model, mice were treated with vehicle, RT, BLZ-945, or RT plus BLZ-945. RESULTS: BLZ-945 reduced M2 polarization in vitro. BLZ-945 alone did not improve median overall survival (mOS=29 days) compared to control mice (mOS=27 days). RT improved survival (mOS=45 days; p=0.02), while RT plus BLZ-945 led to the longest survival (mOS=not reached; p=0.005). Resected tumors had a relatively large population of M2 TAMs in GBM at baseline, which was increased in response to RT. BLZ-945 reduced RT-induced M2 infiltration. CONCLUSION: Inhibition of CSF-1R improved response to RT in the treatment of GBM and may represent a promising strategy to improve RT-induced antitumor immune responses. Copyright
Authors: Shu Liu; Xiangdong Sun; Jinhua Luo; Hongcheng Zhu; Xi Yang; Qing Guo; Yaqi Song; Xinchen Sun Journal: Am J Cancer Res Date: 2015-10-15 Impact factor: 6.166
Authors: Nicholas Butowski; Howard Colman; John F De Groot; Antonio M Omuro; Lakshmi Nayak; Patrick Y Wen; Timothy F Cloughesy; Adhirai Marimuthu; Sam Haidar; Arie Perry; Jason Huse; Joanna Phillips; Brian L West; Keith B Nolop; Henry H Hsu; Keith L Ligon; Annette M Molinaro; Michael Prados Journal: Neuro Oncol Date: 2015-10-08 Impact factor: 12.300
Authors: Ralf S Schmid; Jeremy M Simon; Mark Vitucci; Robert S McNeill; Ryan E Bash; Andrea M Werneke; Lauren Huey; Kristen K White; Matthew G Ewend; Jing Wu; C Ryan Miller Journal: Neuro Oncol Date: 2016-01-28 Impact factor: 12.300
Authors: Erik Ladomersky; Lijie Zhai; Alicia Lenzen; Kristen L Lauing; Jun Qian; Denise M Scholtens; Galina Gritsina; Xuebing Sun; Ye Liu; Fenglong Yu; Wenfeng Gong; Yong Liu; Beibei Jiang; Tristin Tang; Ricky Patel; Leonidas C Platanias; C David James; Roger Stupp; Rimas V Lukas; David C Binder; Derek A Wainwright Journal: Clin Cancer Res Date: 2018-03-02 Impact factor: 12.531
Authors: Emeline Brocard; Kristell Oizel; Lisenn Lalier; Claire Pecqueur; François Paris; François M Vallette; Lisa Oliver Journal: Oncotarget Date: 2015-03-30
Authors: Karl John Habashy; Rana Mansour; Charbel Moussalem; Raymond Sawaya; Michel J Massaad Journal: Br J Cancer Date: 2022-06-04 Impact factor: 9.075